Clinical Trials Browser

Phase 3 × INDUSTRY × Advanced Non-squamous Non-small Cell Lung Cancer × Clear all

NCT05346952 2022-04-26

A Study of TQB2450 Injection Plus Chemotherapy Followed by TQB2450 Plus Anlotinib Versus Tislelizumab Plus Chemotherapy Followed by Tislelizumab in the Treatment of First-line Non-squamous Non-small Cell Lung Cancer(NSCLC).

Phase 3 Unknown

Advanced Non-squamous Non-small Cell Lung Cancer